NCNathalie Cassoux

Nathalie Cassoux

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathalie Cassoux has a total of 263 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comment les médecins communiquent le pronostic génomique auprès des patients atteints de mélanome uvéal ? Résultats d’une étude qualitative

    by Anita Müller, Pauline Vaflard, Marie-France Mamzer, Nathalie Cassoux, Anne Bredart, Manuel Rodrigues, Sylvie Dolbeault

  • Open Access

    Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France – protocol of a prospective observational mixed-method study

    by Anita Müller, Sylvie Dolbeault, Sophie Piperno-Neumann, Morgane Clerc, Paulin Jarry, Nathalie Cassoux, Livia Lumbroso-Le Rouic, Alexandre Matet, Manuel Rodrigues, Bernhard Holzner, et al.

    Quality of life (QoL) in patients undergoing surveillance for uveal melanoma (UM) can be affected by psychological sequelae. Fear of cancer recurrence (FCR) may be acute especially when prognostication indicates an increased risk of metastatic recurrence. Communication with an ophthalmologist or oncologist can then play a key role in impacting QoL. In this prospective study co-designed with patient’s partners and using a mixed-method approach, 250 patients at high versus low risk of metastatic recurrence are recruited in a national UM reference centre in France. At T1, after the 6-months post-treatment surveillance visit, dyads of clinicians and eligible patients complete a questionnaire to assess their respective experience of the communication during that consultation. Patients also complete questionnaires assessing their health literacy, information preference, and satisfaction with the information received (EORTC QLQ-INFO25), genomic testing knowledge, genomic test result receipt, satisfaction with medical care (EORTC PATSAT-C33), perceived recurrence risk, anxiety and depression (HADS), fear of cancer recurrence (FCRI) and quality of life (EORTC QLQ-C30 and QLQ-OPT30). At 12-months post-treatment (T2), patients complete again the HADS, FCRI, EORTC QLQ-C30 and QLQ-OPT30. Multilevel analyses will assess the effect of satisfaction with the information received on FCR and QoL accounting for the clinicians’ and patients’ characteristics. In-depth interviews planned sequentially with ≈25 patients will deepen understanding of patients’ care experience. As information on prognosis based on medical parameters becomes widely integrated into oncology practice, this study will highlight UM survivors’ information expectations and satisfaction with communication, and its effect on FCR and QoL. Culturally adapted recommendations for doctor-patient communication will be provided for contexts of oncology surveillance involving poor prognosis in cases of recurrence. NCT06073548 (October 4, 2023).


  • Open Access

    Divergent local and systemic antitumor response in primary uveal melanomas

    by Francesca Lucibello, Ana I. Lalanne, Anne-Laure Le Gac, Abdoulaye Soumare, Setareh Aflaki, Joanna Cyrta, Lea Dubreuil, Martin Mestdagh, Marion Salou, Alexandre Houy, et al.

    Uveal melanoma (UM) is the most common cancer of the eye. The loss of chromosome 3 (M3) is associated with a high risk of metastases. M3 tumors are more infiltrated by T-lymphocytes than low-risk disomic-3 (D3) tumors, contrasting with other tumor types in which T cell infiltration correlates with better prognosis. Whether these T cells represent an antitumor response and how these T cells would be primed in the eye are both unknown. Herein, we characterized the T cells infiltrating primary UMs. CD8+ and Treg cells were more abundant in M3 than in D3 tumors. CD39+PD-1+CD8+ T cells were enriched in M3 tumors, suggesting specific responses to tumor antigen (Ag) as confirmed using HLA-A2:Melan-A tetramers. scRNAseq-VDJ analysis of T cells evidenced high numbers of proliferating CD39+PD1+CD8+ clonal expansions, suggesting in situ antitumor Ag responses. TCRseq and tumor-Ag tetramer staining characterized the recirculation pattern of the antitumor responses in M3 and D3 tumors. Thus, tumor-Ag responses occur in localized UMs, raising the question of the priming mechanisms in the absence of known lymphatic drainage.


  • Open Access

    Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients

    by Hélène Salaün, Leanne de Koning, Mathilde Saint-Ghislain, Vincent Servois, Toulsie Ramtohul, Agathe Garcia, Alexandre Matet, Nathalie Cassoux, Pascale Mariani, Sophie Piperno-Neumann, et al.

    Although combined PD-1/CTLA-4 inhibition showed limited efficacy in single-arm, phase II trials in metastatic uveal melanoma (mUM), such combination appears frequently used in mUM patients. We here report our experience with nivolumab/ipilimumab in mUM. A retrospective cohort of 47 mUM patients, 24 men and 23 women, received nivolumab/ipilimumab between October 2019 and December 2021, mostly first line (94%). Two regimens were used: nivolumab 1 mg/kg + ipilimumab 3 mg/kg (nivo1ipi3, 49% of patients) and nivolumab 3 mg/kg + ipilimumab 1 mg/kg (nivo3ipi1, 51% of patients). Median follow-up was 37 and 88 weeks in nivo3ipi1 and nivo1ipi3 cohorts, respectively. We observed partial response in two patients (4%) and stable disease in 14 patients (30%), with no significant difference between the two regimens. Median progression-free survival was 13.6 weeks and 11.9 weeks in the nivo1ipi3 and nivo3ipi1 cohorts, respectively (p = 0.49). Severe adverse events (grade 3 or 4) were observed in seven patients (15%) among which five treated with nivo1ipi3 (22%) and two treated with nivo3ipi1 (8%). These data suggest that nivolumab/ipilimumab combination does not improve clinical outcomes compared to other therapies but is more toxic. In the absence of controlled clinical trials, we would not recommend this combination as a standard treatment in all mUM patients but rather as an option. Patients for whom the benefit–risk ratio could justify the combination need to be defined.


  • MBD4 deficiency is predictive of response to immune checkpoint inhibitors in metastatic uveal melanoma patients

    by Mathilde Saint-Ghislain, Anne-Céline Derrien, Lionnel Geoffrois, Lauris Gastaud, Thierry Lesimple, Sylvie Negrier, Nicolas Penel, Jean-Emmanuel Kurtz, Yannick Le Corre, Caroline Dutriaux, et al.


  • L1CAM and laminin vascular network: Association with the high-risk replacement histopathologic growth pattern in uveal melanoma liver metastases

    by Raymond Barnhill, Steven van Laere, Peter Vermeulen, Sergio Roman-Roman, Sophie Gardrat, Samar Alsafadi, Malcy Tarin, Gabriel Champenois, André Nicolas, Alexandre Matet, et al.


  • Open Access

    Multi-omics comparison of malignant and normal uveal melanocytes reveals novel molecular features of uveal melanoma

    by David Gentien, Elnaz Saberi-Ansari, Nicolas Servant, Ariane Jolly, Pierre de la Grange, Fariba Némati, Géraldine Liot, Simon Saule, Aurélie Teissandier, Deborah Bourchis, et al.

    Uveal Melanoma (UM) is a rare cancer resulting from transformation of melanocytes residing in the uveal tract. Integrative analysis has identified four molecular and clinical subsets in UM. To improve our molecular understanding of UM we performed extensive multi-omics characterization comparing two aggressive UM patient-derived xenograft models with normal choroidal melanocytes, including DNA optical mapping, specific histone modifications, and DNA topology analysis by Hi-C. Our gene expression and cytogenetic analyses suggest that genomic instability is a hallmark of UM. We also identified a recurrent deletion in the BAP1 promoter resulting in loss of expression and associated with high risk of metastases in UM patients. Hi-C revealed chromatin topology changes associated with up-regulation of PRAME , an independent prognostic biomarker in UM and potential therapeutic target. Our findings illustrate how multi-omics approaches can improve the understanding of tumorigenesis and reveals two novel mechanisms of gene expression dysregulation in UM.


  • Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis

    by Irene Jiménez, Éléonore Frouin, Mathieu Chicard, Catherine Dehainault, Jessica Le Gall, Camille Benoist, Arnaud Gauthier, Eve Lapouble, Claude Houdayer, François Radvanyi, et al.


  • Open Access

    Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study

    by Marion Lam, Valérie Touitou, Sylvain Choquet, Nathalie Cassoux, Hervé Ghesquières, Laurent Kodjikian, Anna Schmitt, Sarra Gattoussi, Émeline Tabouret, Magali Sampo, et al.

    The treatment of primary vitreoretinal lymphoma (PVRL) remains controversial regarding the use of local, systemic, or combined treatments. The aim of this study was to analyze the efficacy and toxicity of intravenous high‐dose methotrexate (IV HD‐MTX) based systemic therapy in a uniformly treated population of PVRL patients. From a nationwide French database, we retrospectively selected 59 patients (median age: 70 years, median Karnofsky Performance Status: 90%) with isolated PVRL at diagnosis who received first‐line treatment with HD‐MTX between 2011 and 2018. 8/59 patients also received a local treatment. No deaths or premature discontinuations of MTX due to toxicity were reported. A complete response was obtained in 40/57 patients after chemotherapy. Before treatment, IL‐10 was elevated in the aqueous humor (AH) or in the vitreous in 89% of patients. After treatment, AH IL‐10 was undetectable in 87% of patients with a CR/uCR/PR and detectable in 92% of patients with PD/SD. After a median follow‐up of 61 months, 42/59 (71%) patients had relapsed, including 29 isolated ocular relapses as the first relapse and a total of 22 brain relapses. The median overall survival, progression‐free survival, ocular‐free survival and brain‐free survival were 75, 18, 29 and 73 months, respectively. IV HD‐MTX based systemic therapy as a first‐line treatment for isolated PVRL is feasible, with acceptable toxicity, even in an elderly population. This strategy seems efficient to prevent brain relapse with prolonged overall survival. However, the ocular relapse rate remains high. New approaches are needed to improve local control of this disease, and ocular assessment could be completed by monitoring AH IL‐10.


  • Contributors

    by Camille Alam, Guohua An, Francine Behar-Cohen, Reina Bendayan, Oscar Briz, Nathalie Cassoux, Salvatore Cisternino, Xavier Declèves, Silvia Di Giacomo, Thomas Efferth, et al.